0001104659-21-043756 | 10-K | XBRL Viewer | Fennec Pharmaceuticals INC

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2020	Mar. 29, 2021	Jun. 30, 2020
Document and Entity Information
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Entity Registrant Name	FENNEC PHARMACEUTICALS INC.
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	FENCF
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,002,853
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Central Index Key	0001211583
Amendment Flag	false
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Public Float			$ 116,145,143

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 30,344	$ 13,650
Prepaid expenses	797	226
Other current assets	276	8
Total current assets	31,417	13,884
Non-current assets
Deferred issuance costs	466	326
Deferred issuance cost (amortization)	(466)	(64)
Total non-current assets:		262
Total assets	31,417	14,146
Current liabilities
Accounts payable	1,571	1,612
Accrued liabilities	776	659
Total current liabilities	2,347	2,271
Total liabilities	2,347	2,271
Commitments and Contingencies (Note 7)
Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 26,003 shares issued and outstanding (201919,896)	140,733	106,392
Additional paid-in capital	49,234	48,271
Accumulated deficit	(162,140)	(144,031)
Accumulated other comprehensive income	1,243	1,243
Total stockholders' equity	29,070	11,875
Total liabilities and stockholders' equity	$ 31,417	$ 14,146

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2020	Dec. 31, 2019
Consolidated Balance Sheets
Common stock, no par value	$ 0	$ 0
Common stock, shares issued	26,003	19,896
Common stock, shares outstanding	26,003	19,896

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 5,105	$ 5,607
General and administrative	12,950	7,402
Total operating expenses	18,055	13,009
Loss from operations	(17,885)	(13,009)
Other income/(expense):
Amortization expense	(402)	(64)
Unrealized gain on securities	100	0
Other (loss)/income	(9)	(17)
Interest income	87	315
Total other (expense)/income	(224)	234
Net loss	$ (18,109)	$ (12,775)
Loss per common share, basic and diluted	$ (0.76)	$ (0.64)
Weighted-average number of common shares outstanding basic and diluted (Note 3)	23,704	19,896
Eniluracil royalty
Revenue	$ 170	$ 0

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating activities:
Net loss	$ (18,109)	$ (12,775)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred issuance cost	402	64
Stock-based compensation - consultants	84	417
Stock-based compensation - employees	2,791	2,665
Changes in operating assets and liabilities:
Prepaid expenses	(163)	(58)
Other assets	(268)	(7)
Accounts payable	(41)	580
Accrued liabilities	(291)	54
Net cash used in operating activities	(15,595)	(9,060)
Financing activities:
Cash paid for issuance costs	(140)	(71)
Issuance of shares, options exercise	462	0
Issuance of shares, net of issuance costs	31,967	0
Net cash provided by/used in financing activities	32,289	(71)
Increase in cash and cash equivalents	16,694	(9,131)
Cash and cash equivalents - Beginning of year	13,650	22,781
Cash and cash equivalents - End of year	30,344	13,650
Non-cash investing and financing activities:
Non-cash financing (insurance policy)	408	0
Non-cash deferred issuance cost (warrant value)	$ 0	$ 255

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock Employees	Common Stock Consultants	Common Stock	Additional Paid-in Capital Employees	Additional Paid-in Capital Consultants	Additional Paid-in Capital	Accumulated Deficit Employees	Accumulated Deficit Consultants	Accumulated Deficit	Accumulated Other Comprehensive Income Employees	Accumulated Other Comprehensive Income Consultants	Accumulated Other Comprehensive Income	Employees	Consultants	Total
Balance at Dec. 31, 2018			$ 106,392			$ 44,934			$ (131,256)			$ 1,243			$ 21,313
Balance (in shares) at Dec. 31, 2018			19,896
Stock options issued	$ 0	$ 0		$ 2,665	$ 417		$ 0	$ 0		$ 0	$ 0		$ 2,665	$ 417
Warrants issued to consultants			$ 0			255			0			0			255
Net loss			0			0			(12,775)			0			(12,775)
Balance at Dec. 31, 2019			$ 106,392			48,271			(144,031)			1,243			11,875
Balance (in shares) at Dec. 31, 2019			19,896
Stock options issued	$ 0	$ 0		$ 2,791	$ 84		$ 0	$ 0		$ 0	$ 0		$ 2,791	$ 84
Issuance of securities			$ 31,967			0			0			0			31,967
Issuance of securities (in shares)			5,460
Exercise of stock options			$ 2,374			(1,912)			0			0			462
Exercise of stock options (in shares)			647
Net loss			$ 0			0			(18,109)			0			(18,109)
Balance at Dec. 31, 2020			$ 140,733			$ 49,234			$ (162,140)			$ 1,243			$ 29,070
Balance (in shares) at Dec. 31, 2020			26,003

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

Nature of Business and Liquidity	12 Months Ended
Nature of Business and Liquidity	Dec. 31, 2020
Nature of Business and Liquidity
Nature of Business and Liquidity	1. Nature of Business and Liquidity Fennec Pharmaceuticals Inc. (“Fennec,” “the Company,” “we,” “us,” or “our”) was originally formed as a British Columbia corporation under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014. Fennec, together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation and Fennec Pharmaceuticals (EU) Limited (“Fennec Limited”), collectively referred to herein as the “Company,” is a biopharmaceutical company with a product candidate under development for use in the treatment of cancer. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive. These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2020, the Company incurred a loss from operations of $17,885 and still has not earned any significant revenue in its history from the commercial sale of its product candidate. At December 31, 2020 it had an accumulated deficit of $162,140 and had experienced negative cash flows from operating activities in the amount of $15,595 for the year ended December 31, 2020. On May 5, 2020, the Company announced the completion of an underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share. In addition, Fennec issued an additional 660,204 common shares in connection with the partial exercise of the underwriters’ over-allotment option. The approximate total gross proceeds from the offering was $34,100 ($32,189 net of commissions, fees and issue costs). On February 1, 2019, Fennec entered into a Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank, an Arizona corporation, pursuant to which the Bank agreed to loan $12.5 million to the Company, to be made available upon New Drug Application (“NDA”) approval of PEDMARKTM by no later than September 30, 2020. The proceeds from the loan will be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Interest under the Term Loans shall bear interest, on the outstanding daily balance thereof, at a floating per annum rate equal to the Effective Interest Rate (as defined in the Loan and Security Agreement) which is equal to the sum of the Prime Rate published in the Wall Street Journal (currently 3.25%) plus one percent (1.00%). The debt facility is to have interest-only monthly payments due for the first eighteen months from the funding date and then monthly principal and interest payments are due through the remainder of the term which has a maturity date of October 1, 2023. In connection with the facility, Fennec has agreed to grant Bridge Bank a warrant to purchase up to 39,130 common shares at an exercise price of $6.80 per common share, for a term of ten years from the date of issuance, subject to early termination under certain conditions. On June 26, 2020, Fennec announced an amendment to the Loan and Security Agreement with Bridge Bank. This amendment provides Fennec with an $18.0 million debt facility comprised of two term loans. Term Loan A consists of $12.5 million to be funded upon NDA approval of PEDMARKTM in the U.S. to be made available upon NDA approval of PEDMARKTM by no later than December 31, 2020 and Term Loan B consists of $5.5 million to be funded upon the occurrence of a revenue event in 2021. The interest-only period for the facility has the ability to be extended from 18 months to 24 months from the funding of Term Loan A, provided that Term Loan B is funded, and certain conditions are met. The fee in connection with Loan B, can either be 2.13% of the Loan B amount in cash, or the Company can issue a warrant with a value equal to 3.25% of the Loan B amount. On August 6, 2020, the Company paid cash for the extended facility. These statements reflect that fee being settled with cash instead of a warrant. Under Accounting Standards Codification ("ASC") 470-50, Modifications and Extinguishments, the amendment was considered a modification. As such, the Company had been amortizing the loan fee and the value of the warrant over the remainder of the loan term. Following the receipt of the U.S. Food and Drug Administration’s (“FDA”) Complete Response Letter (“CRL”), management decided to fully amortize the remaining portions of the loan fee and the value of the warrants. On August 10, 2020, the Company received a CRL from the FDA regarding its NDA for PEDMARKTM. According to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies that are required to be resolved prior to the approval of PEDMARKTM. Importantly, no clinical safety or efficacy issues were identified during the review and there is no requirement for further clinical data. The Company plans to work closely with the third-party drug manufacturer and the FDA to fully address the CRL and plans to resubmit the NDA for PEDMARKTM in the second quarter of 2021. The Company believes the funds raised in the public offering which closed in May 2020 provide sufficient funding for the Company to carry out its planned activities including potential NDA approval and the commencement of commercialization efforts for at least the next twelve months as it continues its strategic development of PEDMARKTM. These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Significant Accounting Policies

Significant Accounting Policies

2. Significant Accounting Policies

Basis of presentation

The consolidated financial statements include the accounts of Fennec and of all its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation.

Use of estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of stock-based compensation. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.

The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2020, the Company had $30.3 million in cash and money market accounts (2019‑ $13.7 million). Money market investments typically have minimal risks. While the Company has not experienced any loss or write-down of its money market investments, the amounts it holds in money market accounts are substantially above the $250,000 amount insured by the FDIC and may lose value.

Financial instruments

Financial instruments recognized on the balance sheets at December 31, 2020 and December 31, 2019 consist of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying values of which, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading.

The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.

The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trading or speculative nature.

Common shares and warrants

The Company has 0.04 million warrants with a weighted average strike price of $6.80 outstanding to purchase common shares that were denominated in United States dollars (“USD”).

Revenue

The Company's revenue is generated through sales of intellectual property (“IP”). The Company generates its revenue through one segment and the revenue recognized under each of the Company's arrangements during the current period is described below. The terms of these agreements may contain multiple promised goods or services or optional goods and services, including licenses to product candidates, referred to as exclusive licenses, as well as research and development activities to be performed by the Company on behalf of the collaboration partner related to the licensed product candidates.

Revenue recognition

Revenue is recognized when control of the promised goods or services are transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or providing services. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.

When determining whether the customer has obtained control of the goods or services, the Company considers the point at which the customer may benefit from the goods or services. For sale of IP to, revenue is recognized upon grant or transfer of the IP, as the Company's IP is considered functional in nature.

Performance obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may contain multiple performance obligations if a promise to transfer goods or services is separately identifiable from other promises in a contract and, therefore, is considered distinct. For contracts with multiple performance obligations, the Company determines the standalone selling price of each performance obligation and allocates the total transaction price using the relative selling price basis. The Company recognizes performance obligations based on their nature.

Significant payment terms

The Company’s revenue arrangements include payments to the Company of one or more of the following: a non-refundable, upfront payment; milestone payments and royalties on commercial sales of IP product candidates, if any. To date, the Company has received upfront payments and several milestone payments but has not received any license or option fees or earned royalty revenue as a result of product sales.

Under ASC 606, the Company estimates the amount of consideration to which it will be entitled in exchange for satisfying performance obligations. Based on the Company’s current contracts, variable consideration primarily exists in the following forms: development and regulatory milestones, royalties and sales-based milestones. The Company utilizes the "most likely amount" variable consideration method for estimating development and regulatory milestone consideration to include in the transaction price. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company refers to this as the variable consideration constraint.

Due to the uncertainty associated with the occurrence of the underlying events which would trigger development and regulatory milestone consideration under its revenue arrangements, with the exception of certain initial conditions precedent milestones, the Company has concluded the variable consideration associated with all development and regulatory milestones to be fully constrained as of the ASC 606 transition date and as of December 31, 2020, and therefore has not included such consideration in the transaction price for any of its revenue arrangements. The Company will reassess this conclusion at each subsequent reporting period and will only include amounts associated with regulatory or development milestones in the transaction price when, or if, the variable consideration is determined to be released from the constraint.

In accordance with ASC 606, the Company is required to adjust the transaction price for the effects of the time value of money if the timing of payments agreed to by the parties to the contract, explicitly or implicitly, provides the Company or its customer with a significant benefit of financing the transfer of goods or services. The Company concluded that its licensing and collaboration arrangements do not contain a significant financing component because the payment structure of its agreements arise from reasons other than providing a significant benefit of financing.

Contract assets

The Company did not have a contract asset as of December 31, 2020 or 2019.

Contract liabilities

The Company did not have a contract liability as of December 31, 2020 or 2019.

Revenue arrangements

Elion

In May 2016, Fennec Pharmaceuticals Inc. (Fennec or the “Company”) sold Eniluracil to Elion Oncology, LLC (Elion). The agreement called for $40,000 in cash and 5% royalties to be paid to Fennec for any income derived from the sale of Eniluracil. The agreement was for the sale, not license of IP. In addition, the agreement did not call for any additional good or service beyond the transfer of IP and related assets (e.g. “all information and know-how”, documentation, etc.).

In August 2020, Elion entered into a license agreement with Processa Pharmaceuticals, Inc. (Processa). The license agreement called for equity and cash upon satisfying the “Condition Precedent”, along with development and regulatory milestone payments, Sales Milestone Payments, and Product Royalties. The grant of the license was conditioned upon the “Condition Precedent” which was defined as (i) Processa’s closing of a public offering by October 30, 2020 in which Processa raised at least $15M and (ii) Processa’s shares being listed on NASDAQ. Upon satisfying the “Condition Precedent” Elion was entitled to receive $100,000 in cash and 825,000 in shares of Processa of which the Company is entitled to 5%. In January 2021, the Company received $5,000 in cash and 41,250 restricted shares of Processa common shares.

The agreement between Elion and Processa entitles Elion to the payments outlined in the table below. Fennec would be eligible to receive 5% of the following based on future milestone events:


Milestone Event	Milestone Payment ($)
1st Year Anniversary of Effective Date	100,000 Restricted Shares
2nd Year Anniversary of Effective Date	100,000 Restricted Shares
1st Patient in Dose Confirmation Study	100,000 Restricted Shares
NDA Submission	300,000 Restricted Shares
1st FDA Approval in US	$5,000,000
2nd FDA Approval in US	$3,000,000
1st Regulatory Approval Outside US	$2,000,000
2nd Regulatory Approval Outside US	$2,000,000

The Company notes that the above payments are conditioned upon the “Condition Precedent” and thus even the restricted shares that are due only upon the passage of time are in fact variable. However, once the “Condition Precedent” occurred only the passage of time occur in order for the 1st and 2nd Year Anniversary payments to become due and as such the Company must conclude as of the date the “Condition Precedent” is satisfied that the 1st and 2nd Year Anniversary milestone payments are also probable of coming to fruition and thus should be included in the transaction price during the 4th quarter of 2020 along with the aforementioned “Condition Precedent” payments.

The arrangement with Elion contains consideration that is variable based on the customer’s achievement of certain development and regulatory milestones. The next milestone payment the Company may be entitled to receive is 5,000 restricted shares for 1st patient in Dose Confirmation Study and then another 15,000 restricted shares for the NDA submission. These are considered variable consideration that is fully constrained due to the uncertainty associated with the achievement of the development milestone. The considerations related to royalties (first and second FDA approval in US and first and second regulatory approval outside of US) are also variable consideration that are fully constrained in accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products are sold by Processa and the Company has a present right to payment.

The Company recognized $0.2 million in revenue associated with the aforementioned cash and shares it became entitled to for the year ended December 31, 2020. Due to the one year lockup provision on the Processa shares, the Company deemed it reasonable to apply a liquidity discount of 20% to the valuation of the shares associated with the achievement of the October 30, 2020 milestone. Shares associated with the one- and two-year anniversary milestones had a 30 and 40% liquidity discount applied to their fair market valuations.

Subsequent changes to the fair value of the underlying securities are recognized as unrealized gains or losses on marketable equity securities within the consolidated statement of operations and comprehensive loss.

Research and development costs and investment tax credits

Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.

Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made, and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.

Income taxes

The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December 31, 2020, we maintained a full valuation allowance against our deferred tax assets.

The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740‑10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740‑10, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.

Foreign currency translation

The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency translations are included in results of operations.

Loss per share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number of common shares outstanding includes convertible debentures, stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Accordingly, warrants to purchase 0.04 million of our common shares and options to purchase 3.0 million of our common shares at December 31, 2020, were not included in earnings per share. Such options would have an antidilutive effect. In 2019, options to purchase 3.1 million common shares were excluded from the computation of earnings per share as their inclusion would have been antidilutive.

Recent accounting pronouncements

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 removes certain disclosures, modifies certain disclosures and adds additional disclosures. The Company adopted this ASU on January 1, 2020. Certain disclosures in ASU 2018-13 would need to be applied on a retrospective basis and others on a prospective basis. We concluded after evaluation that ASU 2018-13 has no significant effect on our consolidated financial statements.

In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848). In this ASU, the FASB refines the scope of Topic 848 to clarify that certain optional expedients and exceptions therein for contract modifications and hedge accounting apply to contracts that are affected by the discounting transition. Specifically, modifications related to reference rate reform would not be considered an event that requires reassessment of previous accounting conclusions. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The amendments in the ASU are effective immediately for all entities. Entities may choose to apply the amendments retrospectively as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or prospectively to new modifications from any date within an interim period that includes or is subsequent to January 7, 2021, up to the date that financial statements are available to be issued. The Company chose to apply amendments prospectively and concluded after evaluation that ASU 2021-01 has no significant effect on our consolidated financial statements.

Loss per Share

12 Months Ended

Dec. 31, 2020

Loss per Share

Loss per Share

3. Loss per Share

Loss per common share is presented under two formats: basic loss per common share and diluted loss per common share. Basic loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common shares equivalents (e.g. stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following table sets forth the computation of basic and diluted net loss per share (in thousands except per share data):


	Year Ended
	December 31, 2020		December 31, 2019
Numerator:
Net loss	$	(18,109)	$	(12,775)

Denominator:
Weighted-average common shares, basic		23,704		19,896
Dilutive effect of stock options		—		—
Dilutive effect of warrants		—		—
Incremental dilutive shares		—		—
Weighted-average common shares, diluted		23,704		19,896
Net loss per share, basic and diluted	$	(0.76)	$	(0.64)

The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect (in thousands):


	Year Ended
	December 31, 2020	December 31, 2019
Options to purchase common shares	2,952	3,088
Warrants to purchase common shares	39	39

Stock options

12 Months Ended

Dec. 31, 2020

Stock options

Stock options

4. Stock options

The Compensation Committee of the Board of Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of common shares issuable under the stock option plan from a fixed number of 6.7 million to the number of shares that represents twenty-five percent (25%) of the total number of all issued and outstanding common shares. Based upon the current shares outstanding, a maximum of 6.5 million of our common shares are authorized for issuance under the plan. The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of ten years from the date of grant. The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants. A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, through the year ended December 31, 2020 is below.

Summary of $CAD Option Activity


	Number of
	Options
Share Prices Reported in $CAD	(in thousands)	Range		Weighted Average
Outstanding and exercisable at December 31, 2018	648	$	2.43	$	2.43
Outstanding and exercisable at December 31, 2019	648	$	2.43	$	2.43
Exercised	(648)	$	2.43	$	2.43
Outstanding and exercisable at December 31, 2020	—		—		—

Summary of $USD Option Activity


	Number of
	Options
	(in thousands)	Range		Weighted Average
Outstanding and exercisable at December 31, 2018	1,850	$	0.45 – 12.59	$	3.80
Granted	590		4.26 – 5.91		4.83
Outstanding and exercisable at December 31, 2019	2,440	$	0.45 – 12.59	$	3.80
Granted	705		5.91 – 8.09		6.84
Exercised	(193)		1.05 – 5.10		2.39
Outstanding and exercisable at December 31, 2020	2,952	$	0.45 – 12.59	$	4.82

Summary of $USD Option Remaining Life


		Number Outstanding and Exercisable at
Price in		December 31, 2020	Remaining Life
US Dollars		(in thousands)	(years)
$	0.45	11	1.63
$	0.54	19	1.38
$	0.60	17	1.26
$	0.72	50	2.65
$	0.96	10	2.60
$	1.05	60	2.94
$	1.13	50	4.95
$	1.23	8	4.87
$	1.50	7	0.88
$	1.59	90	4.55
$	2.11	36	6.00
$	2.30	4	4.36
$	2.31	275	3.32
$	2.35	4	4.59
$	2.40	8	2.26
$	2.44	49	5.44
$	2.45	225	6.98
$	2.51	4	4.21
$	2.55	4	3.86
$	2.69	90	5.07
$	2.79	15	5.18
$	2.94	3	2.38
$	3.10	10	6.26
$	3.60	3	3.38
$	3.67	35	6.38
$	4.26	85	8.47
$	4.74	175	8.74
$	4.83	244	8.80
$	5.10	240	6.76
$	5.40	20	8.88
$	5.91	50	9.00
$	6.17	180	9.62
$	6.72	21	6.63
$	6.93	435	9.37
$	7.40	40	9.42
$	8.09	50	9.89
$	8.38	210	7.11
$	10.10	20	6.88
$	10.93	85	7.44
$	12.59	10	7.26
	Total	2,952	7.04

Stock compensation expense for the fiscal years ended December 31, 2020 and 2019 was $2.9 million and $3.1 million respectively. These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted and or vested during the fiscal years ended December 31, 2020 and 2019 was $6.84 and $4.83, respectively. The intrinsic value (being the difference between the share price at December 31, 2020 and exercise price) of stock options exercisable at December 31, 2020 was $12.0 million. The intrinsic value of options exercised during the fiscal year ended December 31, 2020 was $2.8 million. The fair value of all options vested during the fiscal year ended December 31, 2020 was $2.4 million.

The fair values of options granted in fiscal years ended December 31, 2020 and 2019 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions for all options with a ten-year expiration:


	Year Ended December 31, 2020		Year Ended December 31, 2019
Expected dividend	0	%	0	%
Risk-free interest rate	0.63– 1.90	%	1.63– 2.70	%
Expected volatility	136 – 148	%	125 – 179	%
Expected life	10.0 years		4.3 – 10.0 years

The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company’s share price.

Modification of Existing US Dollar Denominated Options

In 2019, the Company modified the terms of all outstanding US denominated options extending the expiration date by a weighted average amount of 2.98 years. The Company recorded option modification expense of approximately $1.34 million in the year ended December 31, 2019, included in the $3.1 million of stock compensation in general and administrative expense, discussed above. Some of the option grants were not fully vested, as a result, the Company will recognize $0.2 million in expense over the next nine quarters. The following table summarizes the effect of the June 18, 2019 transaction:


								Expense		Expense
					Expected			Recognized		Recognized
Exercise Price	Number of	Expiration	Risk Free		Life			$USD		$USD After
$USD	Options	Date	Rate		(Years)	Volatility		6/18/19		6/18/19
0.45	11,111	08/17/2022	2.20	%	3.16	71	%		475		—
0.54	9,259	05/17/2022	2.04	%	2.91	67	%		670		—
0.60	8,333	04/04/2022	2.04	%	2.80	68	%		732		—
0.72	16,666	08/23/2023	2.04	%	4.18	125	%		20,642		—
0.96	3,063	08/06/2023	2.04	%	4.13	126	%		6,126		—
1.05	4,762	11/20/2022	2.04	%	3.43	73	%		1,886		—
1.05	83,333	11/20/2022	2.04	%	3.43	73	%		18,566		—
1.13	50,000	12/11/2025	1.80	%	6.48	130	%		33,193		—
1.23	4,062	11/10/2025	1.80	%	6.40	131	%		5,988		—
1.50	6,666	11/18/2021	2.20	%	2.42	66	%		2,247		—
1.59	132,954	01/24/2024	1.86	%	4.60	122	%		139,829		—
2.11	35,545	12/30/2026	1.83	%	7.53	133	%		12,331		—
2.30	4,346	05/11/2025	1.80	%	5.90	127	%		5,475		—
2.31	275,324	04/25/2024	1.86	%	4.85	123	%		404,154		—
2.35	4,254	08/03/2025	1.80	%	6.13	133	%		5,346		—
2.40	8,332	04/03/2023	2.04	%	3.79	130	%		13,640		—
2.44	49,180	06/06/2026	1.80	%	6.98	136	%		19,729		—
2.45	285,000	07/05/2026	1.83	%	7.05	136	%		114,692		526
2.51	3,984	03/16/2025	1.80	%	5.74	127	%		5,401		—
2.55	3,920	11/07/2024	1.86	%	5.39	124	%		5,529		—
2.69	114,000	12/31/2024	1.80	%	5.54	125	%		164,445		—
2.79	21,790	08/04/2024	1.86	%	5.13	125	%		35,363		—
2.94	3,400	05/17/2023	2.04	%	3.91	129	%		6,633		—
3.10	10,000	05/15/2024	1.83	%	7.79	132	%		3,839		—
3.60	2,778	04/03/2027	1.86	%	4.91	123	%		5,609		—
3.67	35,000	05/17/2027	1.83	%	7.91	133	%		14,951		—
4.83	260,000	04/04/2028	1.93	%	9.80	153	%		5,099		59,074
5.10	250,000	06/27/2027	1.83	%	8.02	132	%		94,204		26,291
6.72	21,150	08/17/2027	1.83	%	8.16	131	%		10,298		—
8.38	210,000	02/06/2028	1.83	%	8.64	146	%		58,434		67,273
10.10	20,000	11/16/2027	1.83	%	8.41	137	%		12,193		—
10.93	85,000	06/08/2028	1.83	%	8.97	149	%		51,289		—
12.59	10,000	04/03/2028	1.83	%	8.79	147	%		6,366		—

	2,110,313							$	1,285,374	$	153,064

Fair Value Measurements

12 Months Ended

Dec. 31, 2020

Fair Value Measurements

Fair Value Measurements

5. Fair Value Measurements

The Company has adopted ASC 820 Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Assets/Liabilities Measured at Fair Value on a Recurring Basis


	Fair Value Measurement at December 31, (in thousands)
	Quoted Price in Active
	Market for Identical				Significant Other			Significant
	Instruments				Observable Inputs			Unobservable Inputs
	Level 1				Level 2			Level 3		Total
	2020		2019		2020		2019	2020	2019	2020	2019
Assets
Cash and cash equivalents	678	(1)	347	(1)	29,666		13,303	—	—	30,344	13,650
Processa common shares	—		—		136	(2)	—	—	—		—

(1)

The Company held approximately, $678,000 in cash as of December 31, 2020, of which approximately, $45,000 was in Canadian funds (translated into U.S. dollars). As of December 31, 2019, the Company held approximately $347,000, of which approximately 30,000 was in Canadian funds (translated into U.S. dollars).

(2)

The Company received 41,250 restricted common shares of Processa (PSCA). The share restriction will expire in three tranches: 50%, 25% and 25% at the 6, 9 and 12 month intervals, respectively from October 30, 2020. At October 30, 2020 PSCA shares were trading at $4.11 per share. The Company applied a 20% liquidity discount to the shares and will mark to market at each balance sheet date.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2020

Stockholders' Equity

Stockholders' Equity

6. Stockholders’ Equity

Authorized capital stock

The Company’s authorized capital stock consists of an unlimited number of shares of no-par common shares.

Warrants to Purchase Common Shares

At December 31, 2020, the Company had 39,130 warrants outstanding to purchase common shares at an exercise price of $6.80. The following table summarized our warrant activity.


	Number of
	Warrants
	(in thousands)		Range		Weighted Average
Outstanding and exercisable at December 31, 2018	$	—	$	—	$	—
Granted		39		6.80		6.80
Outstanding and exercisable at December 31, 2019	$	39	$	6.80	$	6.80
Granted		—		—		—
Outstanding and exercisable at December 31, 2020	$	39	$	6.80	$	6.80

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2020
Commitments and Contingencies
Commitments and Contingencies	7. Commitments and Contingencies Oregon Health & Science University Agreement On February 20, 2013, Fennec entered into a new exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including PEDMARKTM and their use in oncology (the "OHSU Agreement"). OHSU will receive certain milestone payments, royalty on net sales for licensed products and a royalty on any consideration received from sublicensing of the licensed technology. On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the OHSU Agreement, which expands Fennec’s exclusive license to include the use of N-acetylcysteine as a standalone therapy and/or in combination with PEDMARKTM for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product. The term of the OHSU Agreement as amended by Amendment 1 expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement. Sodium thiosulfate is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and that expire in the United States in 2038. The OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the OHSU Agreement. Securities Class Action Suit Following the U.S. Food and Drug Administration’s (FDA’s) CRL regarding its NDA for PEDMARKTM as described in Note 1, a putative lawsuit was filed against us purportedly on behalf of purchasers of the Company’s securities between December 20, 2018 and August 10, 2020. The lawsuit seeks to recover damages for Fennec investors under federal securities laws. While we believe that the lawsuit is without merit and intend to vigorously defend against it, the lawsuit is in its early stages and no assessment can be made as to its likely outcome or whether the outcome will be material to us. This litigation, and any other securities class actions that may be brought against us, could result in substantial costs and a diversion of our management’s attention and resources. Executive Severance In the event of his termination with us other than for cause, we will be obligated to pay Mr. Raykov a one-time severance payment equal to twelve months of salary (currently $430,000). In the event of his termination with us other than for cause, we will be obligated to pay Mr. Andrade a one-time severance payment equal to six months of salary (currently $155,875). In the event of her termination with us other than for cause, we will be obligated to pay Ms. Goel a one-time severance payment equal to three months of salary (currently $90,000).

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2020
Subsequent Events
Subsequent Events	8. Subsequent Events Management has evaluated subsequent events through March 29, 2021, the date the financial statements were available to be issued and has concluded there are no additional events that would require adjustment to our disclosure in the statements.

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Taxes

Income Taxes

9. Income Taxes

The Company operates in both U.S. and Canadian tax jurisdictions. Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows (in thousands except for percentage rates):


	Year Ended			Year Ended
	December 31,			December 31,
	2020			2019
Domestic (loss)/gain	$	(8,784)		$	(9,004)
Foreign loss		(9,283)			(3,734)
Loss before income taxes		(18,067)			(12,738)

Expected statutory rate (recovery)		26.50	%		26.50	%
Expected provision for (recovery of) income tax		(4,788)			(3,376)
Permanent differences		752			901
Change in valuation allowance		3,737			2,193
Effect of foreign exchange rate differences		—			—
Effect of change in future enacted tax rates		—			—
Tax credits and other adjustments		—			—
Effect of tax rate changes and other		299			282
Provision for income taxes	$	—		$	—

The Canadian statutory come tax rate of 26.0 percent is comprised of federal income tax at approximately 15.0 percent and provincial income tax at approximately 11.0 percent.

The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2020 and December 31, 2019:


	December 31,		December 31,
	2020		2019
Future tax assets:
SR&ED expenditures	$	2,086	$	2,086
Income tax loss carryforwards		26,770		23,182
Non-refundable investment tax credits		1,083		1,121
Share issue costs		139		99
Accrued expenses		—		—
Fixed and intangible assets		1,083		1,083
Reserves		—		—
		31,161		27,572
Less: valuation allowance		(31,147)		(27,572)
Net future tax assets	$	14	$	—

Tax Cuts and Jobs Act

On December 22, 2017, the then President of the United States signed into law an Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (commonly known as “the Tax Cuts and Jobs Act or the “TCJA”), which introduced a comprehensive set of tax reforms. The Tax Cuts and Jobs Act significantly revises U.S. tax law by, among other provisions, lowering the Company’s corporate tax rate from 34% to 21% and eliminating or reducing certain income tax deductions.

In December 2017, in accordance with the SEC Staff Accounting Bulletin (“SAB”) 118–Income Tax Accounting Implications of the TCJA, the Company recorded tax effects on a provisional basis based on a reasonable estimate. The TCJA did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance and the Company does not have any offshore earnings from which to record the mandatory transition tax. During 2018, the Company completed its analysis under SAB 118 and no additional tax effects due to rate-remeasurement were required to be recorded.

On March 27, 2020 the US government enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which includes numerous modifications to income tax provisions, including a limitation on business interest expense and net operating loss provisions and the acceleration of alternative minimum tax credits. Given the Company’s history of losses, the CARES Act did not have a material impact on its tax provision.

There are no current income taxes owed, nor are any income taxes expected to be owed in the near term. At December 31, 2020 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry-forwards and non-refundable investment tax credits. The unclaimed amounts and their expiry dates are as listed below:


			Province/
	Federal		State
SR&ED expenditures (no expiry)	$	7,872	$	—
Income tax loss carryforwards (expiry date):
2021		26		—
2022		233		—
2023		1,588		—
2024		4,849		—
2025		6,143		6,169
2026		13,868		2,716
2027		8,136		4,219
2028		10,509		4,164
2029		8,185		2,116
2030		2,608		670
2031		3,378		789
2032		3,491		651
2033		1,789		655
2034		1,812		617
2035		1,804		941
2036		2,208		1,013
2037		4,641		1,638
2038		5,567		—
2039		5,848		—
2040		5,791		—
No expiration		15,114		15,114
Investment tax credits (expiry date):
2020		52
2021		521
2022		379
2023		169
2024		189
2025		82
2026		86
2027		47

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Significant Accounting Policies

Basis of presentation

The consolidated financial statements include the accounts of Fennec and of all its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation.

Use of estimates

New accounting pronouncements

Recent accounting pronouncements

Cash and cash equivalents

Cash and Cash Equivalents

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.

Financial instruments

Common shares and warrants

The Company has 0.04 million warrants with a weighted average strike price of $6.80 outstanding to purchase common shares that were denominated in United States dollars (“USD”).

Revenue

Revenue recognition

Performance obligations

Significant payment terms

Contract assets

The Company did not have a contract asset as of December 31, 2020 or 2019.

Contract liabilities

The Company did not have a contract liability as of December 31, 2020 or 2019.

Revenue arrangements

Elion

The agreement between Elion and Processa entitles Elion to the payments outlined in the table below. Fennec would be eligible to receive 5% of the following based on future milestone events:


Milestone Event	Milestone Payment ($)
1st Year Anniversary of Effective Date	100,000 Restricted Shares
2nd Year Anniversary of Effective Date	100,000 Restricted Shares
1st Patient in Dose Confirmation Study	100,000 Restricted Shares
NDA Submission	300,000 Restricted Shares
1st FDA Approval in US	$5,000,000
2nd FDA Approval in US	$3,000,000
1st Regulatory Approval Outside US	$2,000,000
2nd Regulatory Approval Outside US	$2,000,000

Research and development costs and investment tax credits

Income taxes

Foreign currency translation

The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency translations are included in results of operations.

Loss per share

Loss per Share (Tables)

12 Months Ended

Dec. 31, 2020

Loss per Share

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share (in thousands except per share data):


	Year Ended
	December 31, 2020		December 31, 2019
Numerator:
Net loss	$	(18,109)	$	(12,775)

Denominator:
Weighted-average common shares, basic		23,704		19,896
Dilutive effect of stock options		—		—
Dilutive effect of warrants		—		—
Incremental dilutive shares		—		—
Weighted-average common shares, diluted		23,704		19,896
Net loss per share, basic and diluted	$	(0.76)	$	(0.64)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	Year Ended
	December 31, 2020	December 31, 2019
Options to purchase common shares	2,952	3,088
Warrants to purchase common shares	39	39

Stock options (Tables)

12 Months Ended

Dec. 31, 2020

Fair values of options granted using weighted average assumptions


	Year Ended December 31, 2020		Year Ended December 31, 2019
Expected dividend	0	%	0	%
Risk-free interest rate	0.63– 1.90	%	1.63– 2.70	%
Expected volatility	136 – 148	%	125 – 179	%
Expected life	10.0 years		4.3 – 10.0 years

Canadian Dollar [Member]

Options granted under the stock option plan are exercisable

Summary of $CAD Option Activity


	Number of
	Options
Share Prices Reported in $CAD	(in thousands)	Range		Weighted Average
Outstanding and exercisable at December 31, 2018	648	$	2.43	$	2.43
Outstanding and exercisable at December 31, 2019	648	$	2.43	$	2.43
Exercised	(648)	$	2.43	$	2.43
Outstanding and exercisable at December 31, 2020	—		—		—

Currency, U.S. Dollar [Member]

Options granted under the stock option plan are exercisable

Summary of $USD Option Activity


	Number of
	Options
	(in thousands)	Range		Weighted Average
Outstanding and exercisable at December 31, 2018	1,850	$	0.45 – 12.59	$	3.80
Granted	590		4.26 – 5.91		4.83
Outstanding and exercisable at December 31, 2019	2,440	$	0.45 – 12.59	$	3.80
Granted	705		5.91 – 8.09		6.84
Exercised	(193)		1.05 – 5.10		2.39
Outstanding and exercisable at December 31, 2020	2,952	$	0.45 – 12.59	$	4.82

Options reinstated agreement either expired and cancelled prior to the agreed severance

Summary of $USD Option Remaining Life


		Number Outstanding and Exercisable at
Price in		December 31, 2020	Remaining Life
US Dollars		(in thousands)	(years)
$	0.45	11	1.63
$	0.54	19	1.38
$	0.60	17	1.26
$	0.72	50	2.65
$	0.96	10	2.60
$	1.05	60	2.94
$	1.13	50	4.95
$	1.23	8	4.87
$	1.50	7	0.88
$	1.59	90	4.55
$	2.11	36	6.00
$	2.30	4	4.36
$	2.31	275	3.32
$	2.35	4	4.59
$	2.40	8	2.26
$	2.44	49	5.44
$	2.45	225	6.98
$	2.51	4	4.21
$	2.55	4	3.86
$	2.69	90	5.07
$	2.79	15	5.18
$	2.94	3	2.38
$	3.10	10	6.26
$	3.60	3	3.38
$	3.67	35	6.38
$	4.26	85	8.47
$	4.74	175	8.74
$	4.83	244	8.80
$	5.10	240	6.76
$	5.40	20	8.88
$	5.91	50	9.00
$	6.17	180	9.62
$	6.72	21	6.63
$	6.93	435	9.37
$	7.40	40	9.42
$	8.09	50	9.89
$	8.38	210	7.11
$	10.10	20	6.88
$	10.93	85	7.44
$	12.59	10	7.26
	Total	2,952	7.04

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes the effect of the June 18, 2019 transaction:


								Expense		Expense
					Expected			Recognized		Recognized
Exercise Price	Number of	Expiration	Risk Free		Life			$USD		$USD After
$USD	Options	Date	Rate		(Years)	Volatility		6/18/19		6/18/19
0.45	11,111	08/17/2022	2.20	%	3.16	71	%		475		—
0.54	9,259	05/17/2022	2.04	%	2.91	67	%		670		—
0.60	8,333	04/04/2022	2.04	%	2.80	68	%		732		—
0.72	16,666	08/23/2023	2.04	%	4.18	125	%		20,642		—
0.96	3,063	08/06/2023	2.04	%	4.13	126	%		6,126		—
1.05	4,762	11/20/2022	2.04	%	3.43	73	%		1,886		—
1.05	83,333	11/20/2022	2.04	%	3.43	73	%		18,566		—
1.13	50,000	12/11/2025	1.80	%	6.48	130	%		33,193		—
1.23	4,062	11/10/2025	1.80	%	6.40	131	%		5,988		—
1.50	6,666	11/18/2021	2.20	%	2.42	66	%		2,247		—
1.59	132,954	01/24/2024	1.86	%	4.60	122	%		139,829		—
2.11	35,545	12/30/2026	1.83	%	7.53	133	%		12,331		—
2.30	4,346	05/11/2025	1.80	%	5.90	127	%		5,475		—
2.31	275,324	04/25/2024	1.86	%	4.85	123	%		404,154		—
2.35	4,254	08/03/2025	1.80	%	6.13	133	%		5,346		—
2.40	8,332	04/03/2023	2.04	%	3.79	130	%		13,640		—
2.44	49,180	06/06/2026	1.80	%	6.98	136	%		19,729		—
2.45	285,000	07/05/2026	1.83	%	7.05	136	%		114,692		526
2.51	3,984	03/16/2025	1.80	%	5.74	127	%		5,401		—
2.55	3,920	11/07/2024	1.86	%	5.39	124	%		5,529		—
2.69	114,000	12/31/2024	1.80	%	5.54	125	%		164,445		—
2.79	21,790	08/04/2024	1.86	%	5.13	125	%		35,363		—
2.94	3,400	05/17/2023	2.04	%	3.91	129	%		6,633		—
3.10	10,000	05/15/2024	1.83	%	7.79	132	%		3,839		—
3.60	2,778	04/03/2027	1.86	%	4.91	123	%		5,609		—
3.67	35,000	05/17/2027	1.83	%	7.91	133	%		14,951		—
4.83	260,000	04/04/2028	1.93	%	9.80	153	%		5,099		59,074
5.10	250,000	06/27/2027	1.83	%	8.02	132	%		94,204		26,291
6.72	21,150	08/17/2027	1.83	%	8.16	131	%		10,298		—
8.38	210,000	02/06/2028	1.83	%	8.64	146	%		58,434		67,273
10.10	20,000	11/16/2027	1.83	%	8.41	137	%		12,193		—
10.93	85,000	06/08/2028	1.83	%	8.97	149	%		51,289		—
12.59	10,000	04/03/2028	1.83	%	8.79	147	%		6,366		—

	2,110,313							$	1,285,374	$	153,064

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2020

Fair Value Measurements

Schedule of Assets/Liabilities Measured at Fair Value on Recurring Basis

Assets/Liabilities Measured at Fair Value on a Recurring Basis


	Fair Value Measurement at December 31, (in thousands)
	Quoted Price in Active
	Market for Identical				Significant Other			Significant
	Instruments				Observable Inputs			Unobservable Inputs
	Level 1				Level 2			Level 3		Total
	2020		2019		2020		2019	2020	2019	2020	2019
Assets
Cash and cash equivalents	678	(1)	347	(1)	29,666		13,303	—	—	30,344	13,650
Processa common shares	—		—		136	(2)	—	—	—		—

(1)

(2)

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2020

Stockholders' Equity

Schedule of Warrants Outstanding to Purchase Common Stock


	Number of
	Warrants
	(in thousands)		Range		Weighted Average
Outstanding and exercisable at December 31, 2018	$	—	$	—	$	—
Granted		39		6.80		6.80
Outstanding and exercisable at December 31, 2019	$	39	$	6.80	$	6.80
Granted		—		—		—
Outstanding and exercisable at December 31, 2020	$	39	$	6.80	$	6.80

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Taxes

Schedule of reconciliation of the combined canadian federal and provincial income tax rate with the effective tax rate

A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows (in thousands except for percentage rates):


	Year Ended			Year Ended
	December 31,			December 31,
	2020			2019
Domestic (loss)/gain	$	(8,784)		$	(9,004)
Foreign loss		(9,283)			(3,734)
Loss before income taxes		(18,067)			(12,738)

Expected statutory rate (recovery)		26.50	%		26.50	%
Expected provision for (recovery of) income tax		(4,788)			(3,376)
Permanent differences		752			901
Change in valuation allowance		3,737			2,193
Effect of foreign exchange rate differences		—			—
Effect of change in future enacted tax rates		—			—
Tax credits and other adjustments		—			—
Effect of tax rate changes and other		299			282
Provision for income taxes	$	—		$	—

Schedule of net future tax assets

The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2020 and December 31, 2019:


	December 31,		December 31,
	2020		2019
Future tax assets:
SR&ED expenditures	$	2,086	$	2,086
Income tax loss carryforwards		26,770		23,182
Non-refundable investment tax credits		1,083		1,121
Share issue costs		139		99
Accrued expenses		—		—
Fixed and intangible assets		1,083		1,083
Reserves		—		—
		31,161		27,572
Less: valuation allowance		(31,147)		(27,572)
Net future tax assets	$	14	$	—

Schedule of unclaimed amounts and their expiry dates

The unclaimed amounts and their expiry dates are as listed below:


			Province/
	Federal		State
SR&ED expenditures (no expiry)	$	7,872	$	—
Income tax loss carryforwards (expiry date):
2021		26		—
2022		233		—
2023		1,588		—
2024		4,849		—
2025		6,143		6,169
2026		13,868		2,716
2027		8,136		4,219
2028		10,509		4,164
2029		8,185		2,116
2030		2,608		670
2031		3,378		789
2032		3,491		651
2033		1,789		655
2034		1,812		617
2035		1,804		941
2036		2,208		1,013
2037		4,641		1,638
2038		5,567		—
2039		5,848		—
2040		5,791		—
No expiration		15,114		15,114
Investment tax credits (expiry date):
2020		52
2021		521
2022		379
2023		169
2024		189
2025		82
2026		86
2027		47

Nature of Business and Going Concern - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Jun. 26, 2020	May 05, 2020	Feb. 01, 2019	Dec. 31, 2020	Dec. 31, 2019
Going Concern [Line Items]
Loss from operations				$ (17,885)	$ (13,009)
Accumulated deficit				(162,140)	(144,031)
Cash flows from operating activities				$ (15,595)	$ (9,060)
Issuance of securities (in shares)		4,800,000
Shares issued, exercise price		$ 6.25
Total gross proceeds from the offering		$ 32,189
Net proceeds from public offering		$ 34,100
Overallotment Option
Going Concern [Line Items]
Issuance of securities (in shares)		660,204
Bridge Bank
Going Concern [Line Items]
Line of credit facility, borrowing capacity	$ 18,000
Bridge Bank \| Loan And Security Agreement \| Term Loan A
Going Concern [Line Items]
Shares issued, exercise price			$ 6.80
Line of credit facility, borrowing capacity			$ 12,500
Shares, issued			39,130,000
Debt instrument, variable interest rate			3.25%
Debt instrument, interest rate, stated percentage			1.00%
Bridge Bank \| Term Loan A
Going Concern [Line Items]
Line of credit facility, borrowing capacity	$ 12,500
Bridge Bank \| Term Loan A \| Minimum
Going Concern [Line Items]
Line Of Credit Facility, Interest Only Period	18 months
Bridge Bank \| Term Loan A \| Maximum
Going Concern [Line Items]
Line Of Credit Facility, Interest Only Period	24 months
Bridge Bank \| Term Loan B
Going Concern [Line Items]
Line of credit facility, borrowing capacity	$ 5,500
Line of Credit Facility, Commitment Fee Percentage	2.13%
Bridge Bank \| Term Loan B \| Warrants
Going Concern [Line Items]
Line of Credit Facility, Commitment Fee Percentage	3.25%

Significant Accounting Policies - Additional Information (Details) shares in Thousands, $ in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	May 31, 2016 USD ($)	Dec. 31, 2020 CAD ($) shares	Dec. 31, 2019 CAD ($) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Money market investments				$ 30,300	$ 13,700
Cash		$ 45,000	$ 30,000	678,000	$ 347,000
FDIC insured amount				$ 250,000
Number of Operating Segments		1
Percentage of royalties		5.00%
Options
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares		3,000	3,100
Warrants
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares		39	39
Eniluracil \| Elion
Summary Of Significant Accounting Policies [Line Items]
Cash proceeds from sale of Eniluracil	$ 40,000
Percentage of royalties	5.00%

Significant Accounting Policies (Details) - USD ($)		1 Months Ended		12 Months Ended
Significant Accounting Policies (Details) - USD ($)	Oct. 30, 2020	Jan. 31, 2021	Aug. 31, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalties				5.00%
1st Year Anniversary of Effective Date
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement				100,000
2nd Year Anniversary of Effective Date
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement				100,000
1st Patient in Dose Confirmation Study
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement				100,000
NDA Submission
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement				300,000
1st FDA Approval in US
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment				$ 5,000,000
2nd FDA Approval in US
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment				3,000,000
1st Regulatory Approval Outside US
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment				2,000,000
2nd Regulatory Approval Outside US
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment				$ 2,000,000
Elion \| Restricted shares \| 1st Patient in Dose Confirmation Study
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement				5,000
Elion \| Restricted shares \| NDA Submission
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement				15,000
Processa Pharmaceuticals, Inc \| License agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment		$ 5,000,000
Processa Pharmaceuticals, Inc \| License agreement \| Restricted shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement	41,250	41,250
Revenues				$ 200,000
Lockup period				1 year
Liquidity discount (as a percent)	20.00%			20.00%
Processa Pharmaceuticals, Inc \| License agreement \| Restricted shares \| 1st Year Anniversary of Effective Date
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Liquidity discount (as a percent)				30.00%
Processa Pharmaceuticals, Inc \| License agreement \| Restricted shares \| 2nd Year Anniversary of Effective Date
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Liquidity discount (as a percent)				40.00%
Processa Pharmaceuticals, Inc \| Elion \| License agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum proceeds from public offering			$ 15,000
Upfront payment			$ 100,000,000
Shares to be issued under agreement			825,000

Loss per Share - Computation of Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss	$ (18,109)	$ (12,775)
Denominator:
Weighted-average common shares, basic	23,704	19,896
Incremental dilutive shares	0	0
Weighted-average common shares, dilutive	23,704	19,896
Net (loss) per share, basic and diluted	$ (0.76)	$ (0.64)
Warrants
Denominator:
Dilutive effect of stock options	0	0
Options
Denominator:
Dilutive effect of stock options	0	0

Loss per Share - Outstanding Options and Warrants (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,952	3,088

Stock Options - Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2020 $ / shares shares	Dec. 31, 2020 $ / shares shares	Dec. 31, 2019 $ / shares shares	Dec. 31, 2019 $ / shares shares
Exercised Range		$ 2.43
Canadian Dollar [Member]
Number of Options Outstanding and Exercisable at Beginning \| shares	(648)	(648)	648	648
Number of Options Exercised \| shares	(648)	(648)
Number of Options Outstanding and Exercisable at Ending \| shares	0	0	(648)	(648)
Outstanding and Exercisable Range		$ 2.43		$ 2.43
Outstanding and Exercisable Range		$ 0.00		$ 2.43
Weighted Average Exercise Price Outstanding and Exercisable at Beginning	$ 2.43		$ 2.43
Weighted- Average Exercised	2.43
Weighted Average Exercise Price Outstanding and Exercisable at Ending	$ 0.00		$ 2.43
Currency, U.S. Dollar [Member]
Number of Options Outstanding and Exercisable at Beginning \| shares	2,440	2,440	1,850	1,850
Number of Options Granted \| shares	705	705	590	590
Number of Options Exercised \| shares	(193)	(193)
Number of Options Outstanding and Exercisable at Ending \| shares	2,952	2,952	2,440	2,440
Weighted Average Exercise Price Outstanding and Exercisable at Beginning		$ 3.80		$ 3.80
Weighted- Average Granted		6.84		4.83
Weighted- Average Exercised		2.39
Weighted Average Exercise Price Outstanding and Exercisable at Ending		4.82		3.80
Currency, U.S. Dollar [Member] \| Minimum
Outstanding and Exercisable Range		0.45		0.45
Granted Range		5.91		4.26
Exercised Range		1.05
Outstanding and Exercisable Range		0.45		0.45
Currency, U.S. Dollar [Member] \| Maximum
Outstanding and Exercisable Range		12.59		12.59
Granted Range		8.09		5.91
Exercised Range		5.10
Outstanding and Exercisable Range		$ 12.59		$ 12.59

Stock options - Price In Canadian Dollars (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2018
Weighted Average Remaining Life (years)	2 years 11 months 23 days
Canadian Dollar [Member]
Number Outstanding and Exercisable	(648)	0	648

Stock Options - Price In US Dollars (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Remaining life (years)		2 years 11 months 23 days
Currency, U.S. Dollar [Member]
Number Outstanding and Exercisable	2,952	2,440	1,850
Remaining life (years)	7 years 15 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 045 [Member]
Price in US Dollars	$ 0.45
Number Outstanding and Exercisable	11
Remaining life (years)	1 year 7 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 054 [Member]
Price in US Dollars	$ 0.54
Number Outstanding and Exercisable	19
Remaining life (years)	1 year 4 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 060 [Member]
Price in US Dollars	$ 0.60
Number Outstanding and Exercisable	17
Remaining life (years)	1 year 3 months 4 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 072 [Member]
Price in US Dollars	$ 0.72
Number Outstanding and Exercisable	50
Remaining life (years)	2 years 7 months 24 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 096 [Member]
Price in US Dollars	$ 0.96
Number Outstanding and Exercisable	10
Remaining life (years)	2 years 7 months 6 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 105 [Member]
Price in US Dollars	$ 1.05
Number Outstanding and Exercisable	60
Remaining life (years)	2 years 11 months 9 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 113 [Member]
Price in US Dollars	$ 1.13
Number Outstanding and Exercisable	50
Remaining life (years)	4 years 11 months 12 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 123 [Member]
Price in US Dollars	$ 1.23
Number Outstanding and Exercisable	8
Remaining life (years)	4 years 10 months 13 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 150 [Member]
Price in US Dollars	$ 1.50
Number Outstanding and Exercisable	7
Remaining life (years)	10 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 159 [Member]
Price in US Dollars	$ 1.59
Number Outstanding and Exercisable	90
Remaining life (years)	4 years 6 months 18 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 211 [Member]
Price in US Dollars	$ 2.11
Number Outstanding and Exercisable	36
Remaining life (years)	6 years
Currency, U.S. Dollar [Member] \| Price In Us Dollars 230 [Member]
Price in US Dollars	$ 2.30
Number Outstanding and Exercisable	4
Remaining life (years)	4 years 4 months 10 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 231 [Member]
Price in US Dollars	$ 2.31
Number Outstanding and Exercisable	275
Remaining life (years)	3 years 3 months 26 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 235 [Member]
Price in US Dollars	$ 2.35
Number Outstanding and Exercisable	4
Remaining life (years)	4 years 7 months 2 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 240 [Member]
Price in US Dollars	$ 2.40
Number Outstanding and Exercisable	8
Remaining life (years)	2 years 3 months 4 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 244 [Member]
Price in US Dollars	$ 2.44
Number Outstanding and Exercisable	49
Remaining life (years)	5 years 5 months 9 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 245 [Member]
Price in US Dollars	$ 2.45
Number Outstanding and Exercisable	225
Remaining life (years)	6 years 11 months 23 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 251 [Member]
Price in US Dollars	$ 2.51
Number Outstanding and Exercisable	4
Remaining life (years)	4 years 2 months 16 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 255 [Member]
Price in US Dollars	$ 2.55
Number Outstanding and Exercisable	4
Remaining life (years)	3 years 10 months 10 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 269 [Member]
Price in US Dollars	$ 2.69
Number Outstanding and Exercisable	90
Remaining life (years)	5 years 26 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 279 [Member]
Price in US Dollars	$ 2.79
Number Outstanding and Exercisable	15
Remaining life (years)	5 years 2 months 5 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 294 [Member]
Price in US Dollars	$ 2.94
Number Outstanding and Exercisable	3
Remaining life (years)	2 years 4 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 310 [Member]
Price in US Dollars	$ 3.10
Number Outstanding and Exercisable	10
Remaining life (years)	6 years 3 months 4 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 360 [Member]
Price in US Dollars	$ 3.60
Number Outstanding and Exercisable	3
Remaining life (years)	3 years 4 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 367 [Member]
Price in US Dollars	$ 3.67
Number Outstanding and Exercisable	35
Remaining life (years)	6 years 4 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 426 [Member]
Price in US Dollars	$ 4.26
Number Outstanding and Exercisable	85
Remaining life (years)	8 years 5 months 19 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 474 [Member]
Price in US Dollars	$ 4.74
Number Outstanding and Exercisable	175
Remaining life (years)	8 years 8 months 27 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 483 [Member]
Price in US Dollars	$ 4.83
Number Outstanding and Exercisable	244
Remaining life (years)	8 years 9 months 18 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 510 [Member]
Price in US Dollars	$ 5.10
Number Outstanding and Exercisable	240
Remaining life (years)	6 years 9 months 4 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 540 [Member]
Price in US Dollars	$ 5.40
Number Outstanding and Exercisable	20
Remaining life (years)	8 years 10 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 591 [Member]
Price in US Dollars	$ 5.91
Number Outstanding and Exercisable	50
Remaining life (years)	9 years
Currency, U.S. Dollar [Member] \| Price In Us Dollars 617 [Member]
Price in US Dollars	$ 6.17
Number Outstanding and Exercisable	180
Remaining life (years)	9 years 7 months 13 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 672 [Member]
Price in US Dollars	$ 6.72
Number Outstanding and Exercisable	21
Remaining life (years)	6 years 7 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 693 [Member]
Price in US Dollars	$ 6.93
Number Outstanding and Exercisable	435
Remaining life (years)	9 years 4 months 13 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 740 [Member]
Price in US Dollars	$ 7.40
Number Outstanding and Exercisable	40
Remaining life (years)	9 years 5 months 1 day
Currency, U.S. Dollar [Member] \| Price In Us Dollars 809 [Member]
Price in US Dollars	$ 8.09
Number Outstanding and Exercisable	50
Remaining life (years)	9 years 10 months 21 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 838 [Member]
Price in US Dollars	$ 8.38
Number Outstanding and Exercisable	210
Remaining life (years)	7 years 1 month 10 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 1010 [Member]
Price in US Dollars	$ 10.10
Number Outstanding and Exercisable	20
Remaining life (years)	6 years 10 months 17 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 1093 [Member]
Price in US Dollars	$ 10.93
Number Outstanding and Exercisable	85
Remaining life (years)	7 years 5 months 9 days
Currency, U.S. Dollar [Member] \| Price In Us Dollars 1259 [Member]
Price in US Dollars	$ 12.59
Number Outstanding and Exercisable	10
Remaining life (years)	7 years 3 months 4 days

Stock options - Options Were Granted Based On The Black Scholes Option Pricing Model (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Expected dividend	0.00%	0.00%
Expected life	10 years
Minimum
Risk-free interest rate	0.63%	1.63%
Expected volatility	136.00%	125.00%
Expected life		4 years 3 months 18 days
Maximum
Risk-free interest rate	1.90%	2.70%
Expected volatility	148.00%	179.00%
Expected life		10 years

Stock Options - Modification of Existing US Dollar Denominated Option (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Dec. 31, 2019	Jun. 18, 2019	Dec. 31, 2020	Dec. 31, 2019
Expected Life (Years)			10 years
Currency, U.S. Dollar [Member]
Number of Options				2,110,313
Expense Recognized	$ 153,064	$ 1,285,374
Currency, U.S. Dollar [Member] \| Price In Us Dollars 045 [Member]
Exercise Price	$ 0.45			$ 0.45
Number of Options				11,111
Expiration Date				Aug. 17, 2022
Risk free rate				2.20%
Expected Life (Years)				3 years 1 month 28 days
Volatility Rate				71.00%
Expense Recognized	$ 0	475
Currency, U.S. Dollar [Member] \| Price In Us Dollars 054 [Member]
Exercise Price	$ 0.54			$ 0.54
Number of Options				9,259
Expiration Date				May 17, 2022
Risk free rate				2.04%
Expected Life (Years)				2 years 10 months 28 days
Volatility Rate				67.00%
Expense Recognized	$ 0	670
Currency, U.S. Dollar [Member] \| Price In Us Dollars 060 [Member]
Exercise Price	$ 0.60			$ 0.60
Number of Options				8,333
Expiration Date				Apr. 04, 2022
Risk free rate				2.04%
Expected Life (Years)				2 years 9 months 18 days
Volatility Rate				68.00%
Expense Recognized	$ 0	732
Currency, U.S. Dollar [Member] \| Price In Us Dollars 072 [Member]
Exercise Price	$ 0.72			$ 0.72
Number of Options				16,666
Expiration Date				Aug. 23, 2023
Risk free rate				2.04%
Expected Life (Years)				4 years 2 months 5 days
Volatility Rate				125.00%
Expense Recognized	$ 0	20,642
Currency, U.S. Dollar [Member] \| Price In Us Dollars 096 [Member]
Exercise Price	$ 0.96			$ 0.96
Number of Options				3,063
Expiration Date				Aug. 06, 2023
Risk free rate				2.04%
Expected Life (Years)				4 years 1 month 17 days
Volatility Rate				126.00%
Expense Recognized	$ 0	6,126
Currency, U.S. Dollar [Member] \| Price In Us Dollars 105 [Member]
Exercise Price	$ 1.05			$ 1.05
Number of Options				4,762
Expiration Date				Nov. 20, 2022
Risk free rate				2.04%
Expected Life (Years)				3 years 5 months 5 days
Volatility Rate				73.00%
Expense Recognized	$ 0	1,886
Currency, U.S. Dollar [Member] \| Price In Us Dollars 105 One [Member]
Exercise Price	$ 1.05			$ 1.05
Number of Options				83,333
Expiration Date				Nov. 20, 2022
Risk free rate				2.04%
Expected Life (Years)				3 years 5 months 5 days
Volatility Rate				73.00%
Expense Recognized	$ 0	18,566
Currency, U.S. Dollar [Member] \| Price In Us Dollars 113 [Member]
Exercise Price	$ 1.13			$ 1.13
Number of Options				50,000
Expiration Date				Dec. 11, 2025
Risk free rate				1.80%
Expected Life (Years)				6 years 5 months 23 days
Volatility Rate				130.00%
Expense Recognized	$ 0	33,193
Currency, U.S. Dollar [Member] \| Price In Us Dollars 123 [Member]
Exercise Price	$ 1.23			$ 1.23
Number of Options				4,062
Expiration Date				Nov. 10, 2025
Risk free rate				1.80%
Expected Life (Years)				6 years 4 months 24 days
Volatility Rate				131.00%
Expense Recognized	$ 0	5,988
Currency, U.S. Dollar [Member] \| Price In Us Dollars 150 [Member]
Exercise Price	$ 1.50			$ 1.50
Number of Options				6,666
Expiration Date				Nov. 18, 2021
Risk free rate				2.20%
Expected Life (Years)				2 years 5 months 1 day
Volatility Rate				66.00%
Expense Recognized	$ 0	2,247
Currency, U.S. Dollar [Member] \| Price In Us Dollars 159 [Member]
Exercise Price	$ 1.59			$ 1.59
Number of Options				132,954
Expiration Date				Jan. 24, 2024
Risk free rate				1.86%
Expected Life (Years)				4 years 7 months 6 days
Volatility Rate				122.00%
Expense Recognized	$ 0	139,829
Currency, U.S. Dollar [Member] \| Price In Us Dollars 211 [Member]
Exercise Price	$ 2.11			$ 2.11
Number of Options				35,545
Expiration Date				Dec. 30, 2026
Risk free rate				1.83%
Expected Life (Years)				7 years 6 months 11 days
Volatility Rate				133.00%
Expense Recognized	$ 0	12,331
Currency, U.S. Dollar [Member] \| Price In Us Dollars 230 [Member]
Exercise Price	$ 2.30			$ 2.30
Number of Options				4,346
Expiration Date				May 11, 2025
Risk free rate				1.80%
Expected Life (Years)				5 years 10 months 24 days
Volatility Rate				127.00%
Expense Recognized	$ 0	5,475
Currency, U.S. Dollar [Member] \| Price In Us Dollars 231 [Member]
Exercise Price	$ 2.31			$ 2.31
Number of Options				275,324
Expiration Date				Apr. 25, 2024
Risk free rate				1.86%
Expected Life (Years)				4 years 10 months 6 days
Volatility Rate				123.00%
Expense Recognized	$ 0	404,154
Currency, U.S. Dollar [Member] \| Price In Us Dollars 235 [Member]
Exercise Price	$ 2.35			$ 2.35
Number of Options				4,254
Expiration Date				Aug. 03, 2025
Risk free rate				1.80%
Expected Life (Years)				6 years 1 month 17 days
Volatility Rate				133.00%
Expense Recognized	$ 0	5,346
Currency, U.S. Dollar [Member] \| Price In Us Dollars 240 [Member]
Exercise Price	$ 2.40			$ 2.40
Number of Options				8,332
Expiration Date				Apr. 03, 2023
Risk free rate				2.04%
Expected Life (Years)				3 years 9 months 15 days
Volatility Rate				130.00%
Expense Recognized	$ 0	13,640
Currency, U.S. Dollar [Member] \| Price In Us Dollars 244 [Member]
Exercise Price	$ 2.44			$ 2.44
Number of Options				49,180
Expiration Date				Jun. 06, 2026
Risk free rate				1.80%
Expected Life (Years)				6 years 11 months 23 days
Volatility Rate				136.00%
Expense Recognized	$ 0	19,729
Currency, U.S. Dollar [Member] \| Price In Us Dollars 245 [Member]
Exercise Price	$ 2.45			$ 2.45
Number of Options				285,000
Expiration Date				Jul. 05, 2026
Risk free rate				1.83%
Expected Life (Years)				7 years 18 days
Volatility Rate				136.00%
Expense Recognized	$ 526	114,692
Currency, U.S. Dollar [Member] \| Price In Us Dollars 251 [Member]
Exercise Price	$ 2.51			$ 2.51
Number of Options				3,984
Expiration Date				Mar. 16, 2025
Risk free rate				1.80%
Expected Life (Years)				5 years 8 months 27 days
Volatility Rate				127.00%
Expense Recognized	$ 0	5,401
Currency, U.S. Dollar [Member] \| Price In Us Dollars 255 [Member]
Exercise Price	$ 2.55			$ 2.55
Number of Options				3,920
Expiration Date				Nov. 07, 2024
Risk free rate				1.86%
Expected Life (Years)				5 years 4 months 21 days
Volatility Rate				124.00%
Expense Recognized	$ 0	5,529
Currency, U.S. Dollar [Member] \| Price In Us Dollars 269 [Member]
Exercise Price	$ 2.69			$ 2.69
Number of Options				114,000
Expiration Date				Dec. 31, 2024
Risk free rate				1.80%
Expected Life (Years)				5 years 6 months 15 days
Volatility Rate				125.00%
Expense Recognized	$ 0	164,445
Currency, U.S. Dollar [Member] \| Price In Us Dollars 279 [Member]
Exercise Price	$ 2.79			$ 2.79
Number of Options				21,790
Expiration Date				Aug. 04, 2024
Risk free rate				1.86%
Expected Life (Years)				5 years 1 month 17 days
Volatility Rate				125.00%
Expense Recognized	$ 0	35,363
Currency, U.S. Dollar [Member] \| Price In Us Dollars 294 [Member]
Exercise Price	$ 2.94			$ 2.94
Number of Options				3,400
Expiration Date				May 17, 2023
Risk free rate				2.04%
Expected Life (Years)				3 years 10 months 28 days
Volatility Rate				129.00%
Expense Recognized	$ 0	6,633
Currency, U.S. Dollar [Member] \| Price In Us Dollars 310 [Member]
Exercise Price	$ 3.10			$ 3.10
Number of Options				10,000
Expiration Date				May 15, 2024
Risk free rate				1.83%
Expected Life (Years)				7 years 9 months 15 days
Volatility Rate				132.00%
Expense Recognized	$ 0	3,839
Currency, U.S. Dollar [Member] \| Price In Us Dollars 360 [Member]
Exercise Price	$ 3.60			$ 3.60
Number of Options				2,778
Expiration Date				Apr. 03, 2027
Risk free rate				1.86%
Expected Life (Years)				4 years 10 months 28 days
Volatility Rate				123.00%
Expense Recognized	$ 0	5,609
Currency, U.S. Dollar [Member] \| Price In Us Dollars 367 [Member]
Exercise Price	$ 3.67			$ 3.67
Number of Options				35,000
Expiration Date				May 17, 2027
Risk free rate				1.83%
Expected Life (Years)				7 years 10 months 28 days
Volatility Rate				133.00%
Expense Recognized	$ 0	14,951
Currency, U.S. Dollar [Member] \| Price In Us Dollars 483 [Member]
Exercise Price	$ 4.83			$ 4.83
Number of Options				260,000
Expiration Date				Apr. 04, 2028
Risk free rate				1.93%
Expected Life (Years)				9 years 9 months 18 days
Volatility Rate				153.00%
Expense Recognized	$ 59,074	5,099
Currency, U.S. Dollar [Member] \| Price In Us Dollars 510 [Member]
Exercise Price	$ 5.10			$ 5.10
Number of Options				250,000
Expiration Date				Jun. 27, 2027
Risk free rate				1.83%
Expected Life (Years)				8 years 7 days
Volatility Rate				132.00%
Expense Recognized	$ 26,291	94,204
Currency, U.S. Dollar [Member] \| Price In Us Dollars 672 [Member]
Exercise Price	$ 6.72			$ 6.72
Number of Options				21,150
Expiration Date				Aug. 17, 2027
Risk free rate				1.83%
Expected Life (Years)				8 years 1 month 28 days
Volatility Rate				131.00%
Expense Recognized	$ 0	10,298
Currency, U.S. Dollar [Member] \| Price In Us Dollars 838 [Member]
Exercise Price	$ 8.38			$ 8.38
Number of Options				210,000
Expiration Date				Feb. 06, 2028
Risk free rate				1.83%
Expected Life (Years)				8 years 7 months 21 days
Volatility Rate				146.00%
Expense Recognized	$ 67,273	58,434
Currency, U.S. Dollar [Member] \| Price In Us Dollars 1010 [Member]
Exercise Price	$ 10.10			$ 10.10
Number of Options				20,000
Expiration Date				Nov. 16, 2027
Risk free rate				1.83%
Expected Life (Years)				8 years 4 months 28 days
Volatility Rate				137.00%
Expense Recognized	$ 0	12,193
Currency, U.S. Dollar [Member] \| Price In Us Dollars 1093 [Member]
Exercise Price	$ 10.93			$ 10.93
Number of Options				85,000
Expiration Date				Jun. 08, 2028
Risk free rate				1.83%
Expected Life (Years)				8 years 11 months 19 days
Volatility Rate				149.00%
Expense Recognized	$ 0	51,289
Currency, U.S. Dollar [Member] \| Price In Us Dollars 1259 [Member]
Exercise Price	$ 12.59			$ 12.59
Number of Options				10,000
Expiration Date				Apr. 03, 2028
Risk free rate				1.83%
Expected Life (Years)				8 years 9 months 15 days
Volatility Rate				147.00%
Expense Recognized	$ 0	$ 6,366

Stock options - Modification of Existing Canadian Dollar Denominated Options (Details)	12 Months Ended
	Dec. 31, 2020
Stock options
Expected Life (Years)	10 years

Stock options - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions		12 Months Ended
	Jun. 24, 2010	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 12,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		2,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		2,400
Weighted Average Remaining Life (years)			2 years 11 months 23 days
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 2,900	$ 3,100
Stock or Unit Option Plan Expense			$ 1,340
Plan Maximum Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issuable under Stock Option Plan	6.5
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issuable under Stock Option Plan	6.7
Percentage Of Total Number Of Share Issued and Outstanding	25.00%	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 6.84	$ 4.83

Fair Value Measurements - Assets/Liabilities Measured at Fair Value (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Oct. 30, 2020	Jan. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and cash equivalents			$ 30,344	$ 13,650
Quoted Price in Active Markets for Identical Instruments Level 1 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and cash equivalents			678	347
Significant Other Observable Inputs Level 2 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and cash equivalents			29,666	13,303
Significant Unobservable Inputs Level 3 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and cash equivalents			0	0
Processa Pharmaceuticals, Inc \| Significant Other Observable Inputs Level 2 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common shares			136
Processa Pharmaceuticals, Inc \| Significant Unobservable Inputs Level 3 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common shares			$ 0	$ 0
License agreement \| Processa Pharmaceuticals, Inc \| Restricted shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement	41,250	41,250
Share price	$ 4.11
Liquidity discount (as a percent)	20.00%		20.00%
License agreement \| Processa Pharmaceuticals, Inc \| Restricted shares \| 6 month interval
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expiration of share restriction	50.00%
License agreement \| Processa Pharmaceuticals, Inc \| Restricted shares \| 9 month interval
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expiration of share restriction	25.00%
License agreement \| Processa Pharmaceuticals, Inc \| Restricted shares \| 12 month interval
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expiration of share restriction	25.00%

Fair Value Measurements - Additional Information (Details) $ in Thousands, $ in Thousands	Dec. 31, 2020 CAD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CAD ($)	Dec. 31, 2019 USD ($)
Fair Value Measurements
Cash	$ 45,000	$ 678,000	$ 30,000	$ 347,000

Stockholders' Equity - Warrants to Purchase Common Stock (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Outstanding and exercisable at the beginning	39,000	0
Exercised		39,000
Granted	0	6.80
Outstanding and exercisable at the end	39,000	39,000
Weighted-Average Outstanding, beginning	$ 6.80	$ 0.00
Granted (in dollars per share)	0.00
Weighted-Average Outstanding, end	6.80	6.80
Minimum
Class of Warrant or Right [Line Items]
Exercised (in dollars per share)		6.80
Weighted Average [Member]
Class of Warrant or Right [Line Items]
Weighted-Average Outstanding, beginning	6.80	0.00
Exercised (in dollars per share)		6.80
Granted (in dollars per share)	0.00
Weighted-Average Outstanding, end	$ 6.80	$ 6.80

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Rostislav Raykov [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause	$ 430,000
Robert Andrade [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause	155,875
Goel [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause	$ 90,000

Income Taxes - Canadian federal and provincial income tax rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
Domestic (loss)/gain	$ (8,784)	$ (9,004)
Foreign loss	(9,283)	(3,734)
Loss before income taxes	$ (18,067)	$ (12,738)
Expected statutory rate (recovery)	26.50%	26.50%
Expected provision for (recovery of) income tax	$ (4,788)	$ (3,376)
Permanent differences	752	901
Change in valuation allowance	3,737	2,193
Effect of foreign exchange rate differences	0	0
Effect of change in future enacted tax rates	0	0
Tax credits and other adjustments	0	0
Effect of tax rate changes and other	299	282
Provision for income taxes	$ 0	$ 0

Income Taxes- Future Income Taxes (Recovery) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	$ 31,161	$ 27,572
Less: valuation allowance	(31,147)	(27,572)
Net future tax assets	14	0
SR&ED expenditures [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	2,086	2,086
Non refundable Investment Tax Credits [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	1,083	1,121
Share Issue Costs [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	139	99
Accrued Expenses [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	0	0
Income Tax Loss Carry forwards [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	26,770	23,182
Fixed and intangible assets [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	1,083	1,083
Reserves [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	$ 0	$ 0

Income Taxes - Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Province State [Member]
Income Tax [Line Items]
SR & ED expenditures (no expiry)	$ 0
Province State [Member] \| Year 2020 [Member]
Income Tax [Line Items]
Investment tax credits (expiry date)	0
Province State [Member] \| Year 2021 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Investment tax credits (expiry date)	0
Province State [Member] \| Year 2022 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Investment tax credits (expiry date)	0
Province State [Member] \| Year 2023 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Investment tax credits (expiry date)	0
Province State [Member] \| Year 2024 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Investment tax credits (expiry date)	0
Province State [Member] \| Year 2025 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	6,169
Investment tax credits (expiry date)	0
Province State [Member] \| Year 2026 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,716
Investment tax credits (expiry date)	0
Province State [Member] \| Year 2027 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,219
Investment tax credits (expiry date)	0
Province State [Member] \| Year 2028 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,164
Province State [Member] \| Year 2029 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,116
Province State [Member] \| Year 2030 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	670
Province State [Member] \| Year 2031 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	789
Province State [Member] \| Year 2032 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	651
Province State [Member] \| Year 2033 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	655
Province State [Member] \| Year 2034 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	617
Province State [Member] \| Year 2035 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	941
Province State [Member] \| Year 2036 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,013
Province State [Member] \| Year 2037 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,638
Province State [Member] \| Year 2038 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Province State [Member] \| Year 2039 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Province State [Member] \| Year 2040 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Province State [Member] \| No expiration
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	15,114
Federal [Member]
Income Tax [Line Items]
SR & ED expenditures (no expiry)	7,872
Federal [Member] \| Year 2020 [Member]
Income Tax [Line Items]
Investment tax credits (expiry date)	52
Federal [Member] \| Year 2021 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	26
Investment tax credits (expiry date)	521
Federal [Member] \| Year 2022 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	233
Investment tax credits (expiry date)	379
Federal [Member] \| Year 2023 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,588
Investment tax credits (expiry date)	169
Federal [Member] \| Year 2024 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,849
Investment tax credits (expiry date)	189
Federal [Member] \| Year 2025 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	6,143
Investment tax credits (expiry date)	82
Federal [Member] \| Year 2026 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	13,868
Investment tax credits (expiry date)	86
Federal [Member] \| Year 2027 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	8,136
Investment tax credits (expiry date)	47
Federal [Member] \| Year 2028 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	10,509
Federal [Member] \| Year 2029 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	8,185
Federal [Member] \| Year 2030 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,608
Federal [Member] \| Year 2031 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,378
Federal [Member] \| Year 2032 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,491
Federal [Member] \| Year 2033 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,789
Federal [Member] \| Year 2034 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,812
Federal [Member] \| Year 2035 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,804
Federal [Member] \| Year 2036 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,208
Federal [Member] \| Year 2037 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,641
Federal [Member] \| Year 2038 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	5,567
Federal [Member] \| Year 2039 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	5,848
Federal [Member] \| Year 2040 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	5,791
Federal [Member] \| No expiration
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	$ 15,114

Income Taxes - Additional Information (Details)	12 Months Ended
Income Taxes - Additional Information (Details)	Dec. 31, 2020	Dec. 31, 2019
Income Taxes Disclosure Additional Information [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	26.50%	26.50%
Canadian Statutory Income Tax [Member]
Income Taxes Disclosure Additional Information [Line Items]
Income tax Rate	26.00%
Federal Income Tax [Member]
Income Taxes Disclosure Additional Information [Line Items]
Income tax Rate	15.00%
Provincial Income Tax [Member]
Income Taxes Disclosure Additional Information [Line Items]
Income tax Rate	11.00%